Albinism

Meet the patient

A six-month-old boy from a consanguineous family is referred for "fair skin and wobbly eyes." He has snow-white hair, a pendular nystagmus he dampens by tilting his head, and both irides glow pink-red under the slit-lamp. His mother wants to know if he will go blind.[2]

Before you reach for a label, hold the three questions that decide this child's future: is this albinism at all, or a mimicker? (the eyes answer); which subtype is it? (the skin and the genes answer); and is it one of the two forms that will kill him? (the blood film answers). The whole topic hangs off those three.[1]

Normal workers, a broken factory — the one distinction

Albinism is the only common pigmentary disorder in which the melanocyte count is normal. The cell is present in full numbers; the chemistry fails. That single fact is the hinge of the entire differential, and examiners test it in every viva.[1]

Picture it as a factory. In albinism the workers turn up every morning but the production line makes a defective product — no melanin leaves the door. In vitiligo and piebaldism the workers have been sacked or never arrived, so the factory stands empty. Same pale skin, completely different disease, and a skin biopsy settles it: albinism keeps its melanocytes (carrying only early, poorly melanised melanosomes); vitiligo has lost them altogether.[1]

The consultant confession: when a fair child is referred as "albinism" and the eyes are entirely normal, challenge the label before you extend the workup. True albinism always involves the eye.[4]

Etymology for viva gold: melanin is from the Greek melas, "black"; albus is Latin for "white". The disease is named for what is missing, not for what is broken.[1]

The gene map — name the chromosome, earn the mark

Albinism sorts first by distribution (oculocutaneous versus ocular) and then by gene. The non-syndromic OCAs (OCA1 through OCA8) are all autosomal recessive and share the same ocular tetrad; they differ chiefly in severity, residual pigment, and ancestry. Ocular albinism (OA1) is X-linked recessive and spares the skin and hair.[2][5]

[5]

The gene-chromosome pairs are pure memory work, and they are worth every mark they earn:[5]

• OCA1 — TYR, 11q14. Tyrosinase itself. Total loss of activity abolishes all melanin (OCA1A, the severe tyrosinase-negative form); partial loss allows some pigment (OCA1B).
• OCA2 — P gene, 15q12. The most common OCA worldwide and the dominant type in sub-Saharan Africa.
• OCA3 — TYRP1, 9p23. Rufous albinism; reddish-bronze skin and ginger hair, almost exclusively African.
• OCA4 — SLC45A2, 5p13. Melanosome pH regulation; clinically indistinguishable from OCA2 and enriched in Japanese and Korean cohorts.
• OA1 — GPR143, Xp22. X-linked recessive; males only, eyes only.[5]

The rarer non-syndromic types — OCA5 (4p15.2), OCA6 (SLC24A5), OCA7 (LRMDA), and OCA8 (DCT) — behave like OCA2 and are separated only by gene-panel sequencing.[5]

Who gets it, and why the geography is the prognosis

Albinism is rare globally but devastatingly common in selected populations, a pattern that reflects founder effects and the silent carrier state of recessive inheritance.[1]

[1]

OCA1 leads in European and Japanese populations; OCA2 dominates in sub-Saharan Africa, where the carrier frequency reaches 1 in 25 to 1 in 50 and affected individuals may number 1 in 1,000 in Tanzania and Zimbabwe — the highest prevalence in the world. OCA3 is seen almost exclusively in African populations, and OA1 affects males at roughly 1 in 60,000.[2][6]

Everyone forgets: the dominant risk factors for a bad outcome are environmental, not genetic — consanguinity, equatorial residence with intense year-round ultraviolet exposure, and poor access to sunscreen and dermatology. In much of sub-Saharan Africa these converge, and skin cancer, not the albinism itself, is the leading cause of premature death, with some series reporting a median age at skin-cancer death below 40.[6][9]

The pathway, and where each gene blocks it

Every OCA type maps onto a defined point along the melanin biosynthetic pathway, which is why the pathway earns its viva place.[1]

Melanin is made inside the melanosome, a lysosome-related organelle within the melanocyte. The pathway begins with L-tyrosine. Tyrosinase (encoded by TYR on 11q14) catalyses the first two and rate-limiting steps — hydroxylation of tyrosine to L-DOPA, then oxidation of L-DOPA to dopaquinone. Dopaquinone is the branch point: with cysteine it is shunted into pheomelanin (red-yellow); otherwise it proceeds via dopachrome to eumelanin (brown-black). Both pigments are packaged into stage-IV melanosomes and handed to keratinocytes, where they sit over the nucleus as a parasol against ultraviolet damage.[1]

[1]

Two downstream consequences define the disease. In the skin, the missing melanin removes the natural ultraviolet filter, so photons reach and mutate keratinocyte and melanocyte DNA directly; cumulative actinic damage drives the skin-cancer burden. In the eye, melanin is required by the retinal pigment epithelium and iris during development, and its absence causes foveal hypoplasia, iris transillumination (the pink-red glow at the slit-lamp), and a striking wiring error — abnormal decussation at the chiasm, in which an excess of temporal-retinal fibres cross to the contralateral side.[1]

The chiasmal misrouting is worth a closer look because it is the single most objective laboratory confirmation of albinism available. In normal development the fraction of retinal ganglion-cell axons that cross at the chiasm is set by molecular cues from the retinal pigment epithelium, and melanin signalling is one of the marks that tells a ganglion cell to stay uncrossed (ipsilateral). When melanin is absent, too many fibres cross — including ones that should have remained ipsilateral — producing an asymmetrical cortical representation of each visual hemifield that pattern-reversal VEP detects as a larger contralateral-than-ipsilateral response.[8]

Why the eyes are always involved — the tetrad plus the misrouting

The ocular features are identical across OCA types because the developing eye needs melanin regardless of skin type. The tetrad to reproduce verbatim:[1]

• Nystagmus — involuntary, usually pendular and horizontal, present from infancy; it dampens with age and the child adopts a compensatory null point (an anomalous head posture that minimises the movements).[4]
• Foveal hypoplasia — the fovea never develops its pit or cone mosaic; this is the chief cause of the permanently reduced visual acuity (typically 6/18 to 6/60) and is visible on OCT and fundoscopy as an absent foveal reflex with retinal vessels coursing through the macula.[4]
• Iris transillumination — depigmented iris stroma transmits light; the slit-lamp shows a pink-red glow and visible radial iris vessels. The degree parallels residual pigment (marked in OCA1A, subtle in OCA2).[2]
• Photophobia and strabismus (usually esotropia or exotropia) are near-universal, with reduced stereopsis and an anomalous head posture completing the picture.[8]

Visual acuity is the single best functional measure: OCA1A is typically 6/60, OCA2 and OCA4 cluster around 6/24 to 6/36, and OA1 resembles OCA1. The visual impairment is stable — it does not worsen through life once the developmental window closes.[1]

The skin — read the subtype in the pigment

The skin and hair phenotype tracks the residual melanin-producing capacity of each genotype, which is why the skin "tells you the subtype."[5]

• OCA1A — pure white hair that never darkens, porcelain-white skin that never tans, blue-to-pink irides, and no pigmented naevi or freckles ever. The presence of naevi argues against OCA1A at the bedside.[5]
• OCA1B (yellow variant) — pale at birth but accumulates yellow-tan pigment, naevi, and freckles over the first years; includes the temperature-sensitive sub-variant in which pigment appears only in the cooler extremities (the Siamese-cat pattern).[5]
• OCA2 — the most pigment of the common types: yellow-brown hair, pigmented naevi, freckling in sun-exposed sites, and some tanning ability.[2]
• OCA3 (rufous) — reddish-bronze skin with red-ginger hair, seen almost exclusively in African populations and with milder ocular disease.[5]

The two syndromic forms that kill

This is the section where the humour stops. Two syndromic albinisms are life-threatening, and missing either costs the patient their life. Both arise because the same intracellular machinery that builds the melanosome also builds platelet dense granules and leucocyte lysosomes — so when that machinery breaks, pigment, bleeding, and immunity fall together.[3][7]

The mantra for the whole topic: the eyes tell you it is albinism; the skin tells you the subtype; the blood film tells you if it will kill them.[3]

Hermansky-Pudlak syndrome (HPS) adds a bleeding diathesis (easy bruising, epistaxis, menorrhagia, surgical bleeding) from absent platelet dense granules, progressive pulmonary fibrosis presenting as exertional dyspnoea with a restrictive defect (typically in the third to fifth decade), and a granulomatous colitis that mimics Crohn disease.[7]

Chédiak-Higashi syndrome (CHS) presents with recurrent pyogenic infections (skin, respiratory, perianal) from defective neutrophil degranulation, partial albinism with characteristic silvery metallic hair, hepatosplenomegaly, and the ever-present risk of a sudden accelerated phase that is clinically haemophagocytic lymphohistiocytosis (HLH): fever, hepatosplenomegaly, pancytopenia, hyperferritinaemia, and hypertriglyceridaemia.[3]

What it is NOT — the differential in one table

The differential separates the congenital hypomelanoses (melanocytes present but under-producing) from the acquired and patterned leukodermas (a different defect). The single discriminator is the eye: every true albinism has the ocular tetrad; the mimics do not.[1]

[1]

The cluster rule for the viva: white skin, white hair, and nystagmus with photophobia is albinism until proven otherwise; a white forelock with patchy depigmentation and normal eyes and hearing is piebaldism; a white forelock with deafness or heterochromia is Waardenburg; a fair child with seizures and developmental delay is PKU until screened.[2]

At the bedside — three questions

The focused assessment answers three questions in order: is this an albinism?, which type?, and is there a syndromic component that changes management?[1]

Cutaneous examination documents skin and hair colour, the distribution of pigmented naevi, freckles, and lentigines in sun-exposed areas (their presence favours OCA2 or OCA1B over OCA1A), signs of chronic actinic damage (actinic keratoses, scaling, ulceration), and any lesion suspicious for skin cancer. A Wood lamp delineates the extent of depigmentation; a pinch of hair against a dark background reveals residual pigment.[1]

Ophthalmic examination is the cornerstone. Document visual acuity (distance and near, with and without correction), the nystagmus (type, amplitude, and the null point), and any strabismus. On slit-lamp look for iris transillumination (the pink-red glow and visible radial vessels are pathognomonic). On fundoscopy grade foveal hypoplasia: the foveal reflex is absent or dull, the macula lacks its xanthophyll pit, retinal vessels run uninterrupted through the macula, and the fundus is blond with visible choroidal vessels.[4]

Systemic examination hunts for the syndromic features that change the prognosis: bruising, epistaxis, gum hypertrophy, and signs of blood loss in HPS; hepatosplenomegaly, lymphadenopathy, recurrent infection, silvery hair, and focal neurological signs in CHS; and dyspnoea, fine basal crackles, and finger clubbing in HPS pulmonary fibrosis. Examine parents and siblings, and review the developmental history — CHS causes progressive neurologic decline.[3][7]

Investigations — confirm, type, screen

Albinism is diagnosed clinically and molecularly, not by biopsy. The sequence is: confirm the clinical phenotype, define the ocular anatomy, sequence the genes, and screen for systemic disease when a syndromic form is suspected.[1]

Genetic testing. A multi-gene panel sequencing TYR, OCA2, TYRP1, SLC45A2, SLC24A5, LRMDA, DCT, GPR143, and the HPS genes confirms the subtype, distinguishes OCA from OA1, identifies carriers for counselling, and enables prenatal or preimplantation diagnosis. A historical and still-taught bedside test is the hair-bulb incubation with tyrosine and DOPA: bulbs that fail to darken are tyrosinase-negative (OCA1A); bulbs that darken are tyrosinase-positive (OCA2 and most others).[5]

Ophthalmic investigations. The full work-up includes cycloplegic refraction (high ametropia is common), slit-lamp for iris transillumination, fundus photography, optical coherence tomography (OCT) to grade foveal hypoplasia objectively, visual evoked potentials (VEP) to demonstrate the characteristic asymmetry of chiasmal misrouting (among the most sensitive confirmatory tests), and electroretinography (ERG), which is typically normal because retinal function is preserved — the defect is structural, not degenerative.[8]

[4]

Syndromic investigations. In Hermansky-Pudlak the platelet count is normal but the bleeding time is prolonged; aggregation studies show absent second-wave aggregation with ADP and epinephrine; and platelet electron microscopy (the gold standard) shows absent dense bodies. Add pulmonary function tests and high-resolution CT to stage fibrosis, and screen for colitis if bowel symptoms are present.[7] In Chédiak-Higashi the peripheral film shows giant peroxidase-positive cytoplasmic granules in neutrophils, eosinophils, and lymphocytes (pathognomonic), natural-killer cytotoxicity is reduced, and a suspected accelerated phase demands ferritin, triglycerides, fibrinogen, soluble IL-2 receptor, and marrow haemophagocytosis against HLH criteria.[3]

Skin biopsy is rarely needed. In albinism the melanocytes are present in normal numbers but contain only early, poorly melanised melanosomes — the opposite of vitiligo, where melanocytes are absent altogether. Biopsy does not usually change management.[1]

Management — four pillars and one emergency

There is no cure for albinism. Management is lifelong prevention and support, built on four pillars: photoprotection, skin surveillance, ophthalmology, and genetic and psychosocial support.[2][9]

The newborn with albinism is not an acute emergency, but three situations are time-critical, and examiners expect them recognised:[1]

1. Chédiak-Higashi accelerated phase (HLH). A febrile CHS child with hepatosplenomegaly and falling counts is in the accelerated phase and will die without treatment. Manage as HLH: urgent haematology referral, the HLH-2004 protocol (dexamethasone, etoposide, ciclosporin), supportive care for cytopenias and organ failure, and planning for curative haematopoietic stem cell transplantation.[3]
2. Hermansky-Pudlak with major bleeding. Withhold all antiplatelet drugs and NSAIDs. Treat with desmopressin (DDAVP) 0.3 micrograms/kg intravenously, antifibrinolytics (tranexamic acid), and platelet transfusion for severe or surgical bleeding; recombinant activated factor VII is reserved for refractory cases. Avoid nasal packing that traumatises mucosa unnecessarily.[7]
3. The newly diagnosed newborn. Confirm the diagnosis, institute sun protection from day one, refer to ophthalmology and clinical genetics, and check vitamin D — strict sun avoidance lowers it. Give the family written, age-appropriate information and put them in touch with a patient organisation.[1]

[1]

Pillar 1 — Photoprotection (the single most important intervention)

Photoprotection from birth is the only effective prevention for the skin-cancer burden, and its rigor determines long-term survival in high-ultraviolet environments.[9]

• Broad-spectrum sunscreen SPF 50+ on all exposed skin, every two hours and after swimming or sweating.[9]
• UPF 50+ clothing (long sleeves, long trousers, tightly woven or rated fabric).[9]
• A wide-brimmed hat (brim at least 7.5 cm) and, where possible, a neck flap.[9]
• UV-blocking, wrap-around sunglasses that also protect the adnexa and reduce photophobia.[9]
• Avoid midday sun (10 am to 4 pm); seek shade; rearrange school or work schedules where possible.[9]
• Vitamin D adequacy: strict sun avoidance lowers vitamin D; supplement 400 to 800 IU per day (more if deficient) and monitor.[1]

Pillar 2 — Skin surveillance

• Monthly self-examination using the ABCDE criteria (Asymmetry, Border irregularity, Colour variation, Diameter over 6 mm, Evolution).[6]
• Full-body dermatologist examination at least annually, and every six months in tropical or high-UV regions and after any skin cancer.[6]
• Biopsy any non-healing, growing, ulcerated, or bleeding lesion — and remember that melanoma in albinism may be amelanotic (pink) and easily dismissed.[6]

When a skin cancer is confirmed, treatment follows standard oncologic principles but attends to the field-change burden of chronically photodamaged albino skin. Squamous cell carcinoma in situ (Bowen disease, actinic keratoses) is treated with 5-fluorouracil 5% cream twice daily for three to six weeks, imiquimod 5% three times weekly, cryotherapy, or photodynamic therapy; invasive SCC is managed with wide local excision (4 to 6 mm margins for low-risk lesions, 6 mm or more for high-risk) or Mohs micrographic surgery for head-and-neck lesions, with radiotherapy reserved for patients unfit for surgery; basal cell carcinoma is treated with surgical excision, Mohs surgery, or topical agents for superficial disease.[6]

Pillar 3 — Ophthalmology

No treatment restores foveal development, so the goal is to maximise available vision and reduce symptoms:[1]

• Low-vision aids — magnifiers, large-print materials, electronic reading devices, smartphone accessibility features.[4]
• Refractive correction and dark-tinted, polarised wrap-around lenses or contact lenses to reduce photophobia.[4]
• Prisms to improve an anomalous head posture, and strabismus surgery (typically bimedial recession) for cosmesis and function.[4]
• Nystagmus surgery (the Anderson or Kestenbaum-Anderson procedure) shifts the null point towards the primary position to widen the field of best vision.[4]

Pillar 4 — Genetic and psychosocial support

• Genetic counselling — autosomal recessive OCA carries a 25 percent recurrence risk; X-linked OA1 means carrier females and affected sons. Cascade testing of relatives, and prenatal diagnosis (CVS or amniocentesis) or preimplantation genetic testing (PGT-M) once the familial mutation is known.[5]
• Psychosocial support — address bullying, stigma, and self-esteem; vocational guidance; educational accommodations; and connection with patient organisations such as Under the Same Sun and the Africa Albinism Network.[6]

Hermansky-Pudlak syndrome

HPS is the most common syndromic albinism in many populations and is enriched in Puerto Rico (the HPS1 founder mutation). It is defined by the triad of oculocutaneous albinism, a platelet dense-body deficiency causing a bleeding diathesis, and — in the commoner subtypes — pulmonary fibrosis. At least eleven HPS genes (HPS1 through HPS11) have been identified, all encoding components of the lysosome-related-organelle biogenesis complexes (BLOC-1, BLOC-2, BLOC-3, and AP-3).[7]

Clinically the albinism resembles OCA2 (moderate hypopigmentation with the full ocular tetrad). The bleeding history reflects absent dense granules: the platelet count is normal, the bleeding time prolonged, and aggregation studies show absent second-wave aggregation with ADP and epinephrine. Pulmonary fibrosis is the life-limiting complication in HPS1 and HPS2 — a progressive interstitial lung disease resembling idiopathic pulmonary fibrosis, typically presenting between 30 and 50 years of age with exertional dyspnoea and a restrictive defect. Granulomatous colitis (Crohn-like) and renal failure add further morbidity.[7]

Management combines the general albinism care above with: avoidance of antiplatelet drugs and NSAIDs; desmopressin, antifibrinolytics, and platelet transfusion for bleeding; pirfenidone for HPS1 pulmonary fibrosis (it slows decline); and lung transplantation for end-stage disease. Colitis is treated with corticosteroids and anti-TNF agents.[7]

Chédiak-Higashi syndrome

CHS is rarer and more lethal. Mutations in LYST (lysosomal trafficking regulator, chromosome 1q42) produce abnormally large lysosomes and lysosome-related organelles in every cell. The result is partial oculocutaneous albinism with characteristic silvery metallic hair, recurrent pyogenic infections from defective neutrophil degranulation and chemotaxis, giant peroxidase-positive granules in leucocytes (pathognomonic on the blood film), mild bleeding from platelet dense-body deficiency, and the risk of an accelerated phase (HLH) that is often fatal in the first decade.[3]

The accelerated phase presents with fever, hepatosplenomegaly, lymphadenopathy, pancytopenia, hyperferritinaemia, hypertriglyceridaemia, hypofibrinogenaemia, and haemophagocytosis on marrow. It is treated with the HLH-2004 protocol and curative haematopoietic stem cell transplantation, which corrects the immune defect and prevents the accelerated phase — but does not correct the albinism, and does not prevent a late-onset neurodegenerative syndrome (cerebellar ataxia, peripheral neuropathy, parkinsonism, and cognitive decline) that emerges in survivors in the third and fourth decades.[3]

Ocular albinism type 1 (OA1)

OA1 (Nettleship-Falls) is X-linked recessive (GPR143, Xp22.2), affecting males with the full ocular tetrad while the skin and hair are usually normal or only minimally hypopigmented. Carrier females are clinically normal but show a characteristic mosaic retinal pigment pattern (irregular radially arranged pigmented and depigmented lacunae) on fundoscopy, reflecting X-inactivation lyonisation. The chiasmal misrouting is as marked as in OCA. Management is the ocular and low-vision support above; photoprotection is still advisable, but the skin-cancer risk is far lower than in OCA.[2]

Rarer syndromic entries to name

Two rarer syndromic entries complete the differential and earn viva marks for the candidate who names them. Griscelli syndrome (myosin Va, RAB27A, or MLPH) shares silvery hair and immune dysregulation with CHS but shows normal melanosome number with clumped pigment rather than giant granules — the absence of leucocyte inclusions is the discriminator, and RAB27A-positive type 2 carries the same HLH risk. Cross-McKusick-Breen syndrome (also called Elejalde or neuroectodermal melanolysosomal disease) combines albinism with profound psychomotor retardation and a silvery hair shaft, and overlaps with the syndromic albinisms. The examiner point: whenever silvery hair accompanies albinism, reach for a blood film for giant granules (CHS) and a careful neurodevelopmental assessment.[3][5]

The easily missed presentations

Examiners test the corners deliberately, and several presentations are routinely missed:[1]

• Autosomal recessive ocular albinism — OCA (most often OCA1B or OCA2) with minimal, easily overlooked cutaneous signs, presenting as isolated infantile nystagmus or strabismus. The skin looks normal; the diagnosis rests on the ocular findings plus molecular testing.[4]
• Prader-Willi and Angelman syndromes unmasking OCA2 — the OCA2 gene sits within the 15q11-q13 deletion region; a hypotonic, feeding-difficult, developmentally delayed child who is also strikingly fair may carry a contiguous gene deletion, and recognising it changes the genetic counselling entirely.[5]
• OA1 in a male infant with normal-appearing skin and only nystagmus and photophobia — easily attributed to congenital motor nystagmus until transillumination and VEP are checked.[2]
• CHS in early infancy presenting as recurrent infection rather than a pigmentary disorder — the silvery hair and partial albinism may be subtle, but the giant granules on the blood film are pathognomonic.[3]

Skin cancer — the preventable killer

Skin cancer is the dominant complication of non-syndromic albinism and the leading cause of premature death where ultraviolet exposure is intense. Squamous cell carcinoma is the most common (three-quarters or more occur on the sun-exposed head, neck, and hands), followed by basal cell carcinoma on the face and then melanoma — which in albinism is frequently amelanotic (pink) and easily mistaken for a benign lesion. The lifetime risk is up to 1000-fold that of the general population.[6][9]

The classic trap: an amelanotic melanoma is easily dismissed as a benign pink nodule in lightly pigmented skin. Biopsy any non-healing, growing, or bleeding lesion — the pink patch that fails to heal is the one that kills.[6]

Complications and the pitfalls examiners probe

The complications divide into cutaneous, ocular, and psychosocial, with the syndromic forms adding their own lethal trajectories.[1]

Cutaneous. Skin cancer dominates — see above. In darker-skinned patients OCA2 and OCA3 retain more residual pigment and may be labelled "mild," yet the skin-cancer risk remains very high and surveillance must not be relaxed.[6]

Ocular. The visual impairment is permanent (typically 6/18 to 6/60) and non-progressive after childhood, but it limits education, employment, driving, and independence. Photophobia and strabismus reduce quality of life.[4]

Psychosocial. Albinism carries a heavy social burden everywhere, but it is most severe in parts of sub-Saharan Africa, where deeply rooted misconceptions associate albinism with magical properties and have driven attacks, mutilation, and killings of people with albinism. Stigma, bullying, reduced marriage and employment prospects, and low self-esteem are near-universal and demand active psychosocial support.[6]

The pitfalls examiners probe:[1]

• Missing a syndromic diagnosis. A bleeding history or recurrent infections in a "fair" child must trigger platelet studies (HPS) or a blood film (CHS). Treating only the albinism misses the lethal systemic disease.[3][7]
• Dismissing a pink lesion. Amelanotic melanoma is easily mistaken for a benign nodule — biopsy any non-healing, growing, or bleeding lesion.[6]
• Confusing OCA2 with normal skin in darker-skinned patients, who show more residual pigment; the skin-cancer risk is nonetheless very high.[6]
• Over-operating on nystagmus. Surgery improves the head posture and widens the null point; it does not cure the nystagmus or the visual acuity.[4]
• Neglecting vitamin D in patients practising strict photoprotection.[1]
• Forgetting late neurodegeneration in CHS survivors after successful HSCT.[3]

Prognosis, special populations, and shared care

For non-syndromic OCA and OA1, life expectancy is normal provided skin cancer is prevented through lifelong photoprotection and surveillance. The visual impairment is permanent and stable. Tropical or equatorial residence dramatically worsens the prognosis because of skin cancer, and patients in these environments need the most aggressive surveillance and support.[6][9]

For Hermansky-Pudlak syndrome, prognosis is governed by pulmonary fibrosis (the leading cause of death in HPS1), bleeding, and colitis; survival has improved with pirfenidone and transplantation but remains reduced.[7] For Chédiak-Higashi syndrome, prognosis is poor without HSCT — most untreated children die of infection or the accelerated phase in the first decade, and even successfully transplanted survivors face late neurodegeneration in adulthood.[3]

Newborns and infants are usually diagnosed at birth on the cutaneous and ocular findings; photoprotection and ophthalmology begin immediately, with developmental surveillance for CHS.[1] Children need educational accommodations — front-of-class seating, large print, electronic magnification, and mobility training — alongside active management of bullying and self-esteem, because sun-safety habits built in childhood are the foundation of lifelong skin-cancer prevention.[1]

Pregnancy. OCA does not affect pregnancy itself. Affected parents or known carriers are offered genetic counselling: an autosomal recessive couple has a 25 percent recurrence risk; an OA1 carrier mother has a 50 percent chance each pregnancy of passing the X chromosome to a son (affected) or a daughter (a carrier like her). Prenatal diagnosis (CVS at 11 to 13 weeks or amniocentesis at 15 to 20 weeks) and preimplantation genetic testing (PGT-M) are available once the familial mutation is known.[5]

Disposition is shared care: a dermatologist leads skin surveillance, an ophthalmologist or optometrist leads vision, a clinical geneticist counsels the family, and a haematologist or respiratory physician co-manages HPS and CHS. The primary care physician coordinates vitamin D monitoring, psychosocial support, school and workplace liaison, and ensures the sun-protection habit is sustained across a lifetime.[1]

Evidence and the names that earn marks

The classification rests on several landmark reviews. Grønskov and colleagues (Orphanet Journal of Rare Diseases, 2007) set out the modern OCA classification by gene and chromosome that still anchors teaching.[5] Kruijt and colleagues (Ophthalmology, 2018) defined the phenotypic spectrum of albinism and standardised the grading of foveal hypoplasia.[4] Ather and colleagues (Human Brain Mapping, 2019) detailed the aberrant visual pathway development — the excess chiasmal crossing — that explains the VEP asymmetry and the stereoscopic deficit.[8] The syndromic forms are covered by De Jesus Rojas and Young (Seminars in Respiratory and Critical Care Medicine, 2020) for HPS and Talbert and colleagues (Current Opinion in Hematology, 2023) for CHS.[7][3]

The skin-cancer and photoprotection literature is dominated by the African experience. Nakkazi (Lancet, 2019) documented the devastating skin-cancer burden in people with albinism in Africa,[6] and Wright and Norval (Photochemistry and Photobiology, 2023) reviewed ultraviolet exposure and photoprotective strategies in South Africa.[9] Thawabteh and colleagues (Molecules, 2023) reviewed the biochemistry of skin pigmentation and its therapeutic targets.[1]

[1] [1]

The mnemonic, the mantra, and the viva trap

[1]

The mantra: the eyes tell you it is albinism; the skin tells you the subtype; the blood film tells you if it will kill them.[3]

Ward-round test

Stem 1 — the Tanzanian child (answer)

A Tanzanian child has yellow-brown hair, pigmented naevi, nystagmus, and visual acuity of 6/36. The parents are unaffected. What is the most likely subtype, the gene and chromosome, and the single intervention that most protects this child's life? Model: This is OCA2 — the most common subtype worldwide and the dominant type in sub-Saharan Africa, characterised by residual pigment, pigmented naevi, and a moderate ocular phenotype. The gene is the OCA2 (P) gene on chromosome 15q12-q13, autosomal recessive. The single most life-protecting intervention is lifelong photoprotection (SPF 50+, UPF clothing, hat, sunglasses, sun avoidance) with annual dermatological skin surveillance, because SCC of the head and neck is the leading cause of premature death in this population.[6][9]

Stem 2 — the fair child who bruises (answer)

A fair-haired three-year-old with nystagmus is referred as "OCA2." His mother mentions he bruises easily and had prolonged bleeding after a dental extraction. What must you check, what will it show, and what must you withhold? Model: This is Hermansky-Pudlak syndrome, not simple OCA2. Check a platelet count (normal), a bleeding time (prolonged), platelet aggregation studies (absent second-wave aggregation with ADP and epinephrine), and platelet electron microscopy (absent dense bodies — the gold standard). Add pulmonary function tests and a high-resolution CT to stage fibrosis. Withhold all antiplatelet drugs and NSAIDs for life; treat bleeding with desmopressin, antifibrinolytics, and platelet transfusion as needed.[7]

Stem 3 — the silvery-haired febrile child (answer)

A two-year-old with partial albinism and silvery metallic hair presents with fever, hepatosplenomegaly, and falling blood counts. What is the diagnosis, what does the blood film show, and what is the management? Model: This is the Chédiak-Higashi accelerated phase — haemophagocytic lymphohistiocytosis on the background of CHS. The blood film shows giant peroxidase-positive cytoplasmic granules in leucocytes (pathognomonic). Confirm HLH against HLH-2004 criteria (fever, splenomegaly, cytopenias, hypertriglyceridaemia or hypofibrinogenaemia, haemophagocytosis, low NK activity, ferritin over 500, soluble CD25 elevated) and treat with the HLH-2004 protocol (dexamethasone, etoposide, ciclosporin) with urgent haematology referral and planning for haematopoietic stem cell transplantation. This child will die without it.[3]

References

1. [1]Thawabteh AM, Jibreen A, Karaman D, et al. Skin Pigmentation Types, Causes and Treatment-A Review Molecules, 2023.PMID 37375394
2. [2]Thomas MG, Zippin J, Brooks BP Oculocutaneous Albinism and Ocular Albinism Overview 1993.PMID 37053367
3. [3]Talbert ML, Malicdan MCV, Introne WJ. Chediak-Higashi syndrome Curr Opin Hematol, 2023.PMID 37254856
4. [4]Kruijt CC, de Wit GC, Bergen AA, et al. The Phenotypic Spectrum of Albinism Ophthalmology, 2018.PMID 30098354
5. [5]Grønskov K, Ek J, Brondum-Nielsen K. Oculocutaneous albinism Orphanet J Rare Dis, 2007.PMID 17980020
6. [6]Nakkazi E. People with albinism in Africa: contending with skin cancer Lancet, 2019.PMID 31423986
7. [7]De Jesus Rojas W, Young LR. Hermansky-Pudlak Syndrome Semin Respir Crit Care Med, 2020.PMID 32279294
8. [8]Ather S, Proudlock FA, Welton T, et al. Aberrant visual pathway development in albinism: From retina to cortex Hum Brain Mapp, 2019.PMID 30511784
9. [9]Wright CY, Norval M. Solar Ultraviolet Radiation, Skin Cancer and Photoprotective Strategies in South Africa(†) Photochem Photobiol, 2023.PMID 35841370